ramucirumab

{
  "id": "MLC-T-ONC-007209",
  "term": "ramucirumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug that binds to the protein vascular endothelial growth factor (VEGF) to help keep new blood vessels from forming and is used to treat different types of cancer. It is used alone or with other drugs to treat certain types of non-small cell lung cancer, hepatocellular carcinoma (a type of liver cancer), colorectal cancer, stomach cancer, and gastroesophageal junction cancer. It is also being studied in the treatment of other types of cancer. Ramucirumab may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody. Also called anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Cyramza, and IMC-1121B.",
    "A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells."
  ],
  "synonyms": [
    "anti-VEGFR-2 fully human monoclonal antibody IMC-1121B",
    "Cyramza",
    "IMC-1121B",
    "monoclonal antibody HGS-ETR2"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ramucirumab/"
}